Migraine constitutes a significant burden, not only to the individual suffering from this disabling disease but also to the society via sick leaves and use of health care resources. Two recent registry studies outline the burden of migraine in a Nordic setting and highlight the potential of erenumab, the first monoclonal antibody¹ developed for prevention of migraine, to lower the burden of headache-related societal costs.

Since 1990, migraine has been one of the top five leading causes for disability worldwide, and in 2016 it was ranked the number one cause in people below 502. An extensive Finnish study¹ recently put these global numbers into a Nordic perspective. Here, data from 17,623 individuals with migraine from a registry of occupational health care users* not only confirmed that migraine limits the lives of people living with the disease but also demonstrated its broader impact at a societal level³.